Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Regulus Therapeutics Inc. (RGLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates"
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates"
04/13/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Certificate of Designation of Preferences, Rights and Limitations of Class A-5 Convertible Preferred Stock",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Regulus Therapeutics Announces $15 Million Private Placement of Equity"
03/23/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates"
01/06/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
01/05/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Eleventh Amendment to Loan and Security Agreement, by and between the Company and Oxford Finance LLC",
"Eleventh Amendment to Loan and Security Agreement, by and between the Company and Oxford Finance LLC"
11/30/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Class A-4 Convertible Preferred Stock",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity"
11/24/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Announces Private Placement of Equity"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates"
10/18/2021 8-K Investor presentation
Docs: "Regulus Therapeutics Inc. Corporate Presentation dated October, 2021"
10/12/2021 8-K Other Events  Interactive Data
08/10/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
01/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 26, 2021 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10628 Science Center Drive, Suite 225 San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-..."
12/04/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 1, 2020 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10628 Science Center Drive, Suite 225 San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Certificate of Designation of Preferences, Rights and Limitations of Class A-3 Convertible Preferred Stock",
"Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock",
"Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Class A-2 Convertible Preferred Stock",
"Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Regulus Therapeutics Announces Private Placement of Equity"
12/01/2020 8-K Investor presentation
Docs: "Regulus Therapeutics Inc. corporate slide presentation",
"Regulus Therapeutics Inc. corporate slide presentation"
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2020 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10628 Science Center Drive, Suite 225 San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates"
08/31/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy